1.89 USD
▼-0.04-1.82%
盘后 2.00 0.00%
2026-09-15
市值
$243.37M
市盈率
—
EPS
-0.93
股息率
—
52 周区间
1.02 – 2.66
成交量
758.97K
Beta
0.40
目标价
4.60
52W 低 1.0252W 高 2.66
价格走势
公司简介
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of bre...